Is myasthenia gravis a contraindication for botulinum toxin?

Area of Science:

• Neurology
• Toxicology

Background:

• Botulinum toxin (BTX) is widely used for cosmetic and therapeutic purposes.
• Myasthenia gravis (MG) has traditionally been a contraindication for BTX treatment due to potential risks.
• The safety and efficacy of BTX in patients with MG require further investigation.

Purpose of the Study:

• To evaluate the safety and outcomes of Botulinum toxin (BTX) treatment in patients with myasthenia gravis (MG).
• To determine if BTX should be avoided in patients diagnosed with MG.

Main Methods:

• Retrospective analysis of clinical data from an MG and dystonia specialist clinic.
• Systematic literature review of published cases involving co-existence of MG and BTX treatments.
• Categorization of patients based on the timing of BTX injections relative to MG diagnosis.

Main Results:

• Patients with subclinical MG receiving BTX injections before diagnosis (n=8) all developed significant muscle weakness (100%).
• Patients with diagnosed MG receiving BTX injections after MG diagnosis and treatment (n=10) showed symptom improvement in 80% (n=8) with dose modification.
• One patient case from the clinic illustrates BTX use prior to MG diagnosis.

Conclusions:

• BTX treatment can be associated with significant muscle weakness in patients with undiagnosed or subclinical myasthenia gravis.
• With appropriate management, including MG treatment and dose adjustments, BTX can be used safely and effectively in patients with co-existing MG.
• These findings suggest a potential for successful BTX application in MG patients under careful clinical supervision.